Mark C. Schneyer - May 1, 2023 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, Chief Financial Officer
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
May 1, 2023
Transactions value $
$0
Form type
4
Date filed
5/3/2023, 09:15 PM
Previous filing
Apr 7, 2023
Next filing
May 19, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Stock Options (Right to Buy) Award $0 +89.9K $0.00 89.9K May 1, 2023 Common Stock 89.9K $21.75 Direct F1
transaction ACAD Restricted Stock Units Award $0 +27.3K $0.00 27.3K May 1, 2023 Common Stock 27.3K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the Stock Option will vest and become exercisable on May 1, 2024. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.
F3 The restricted stock units vest in four equal annual installments beginning May 1, 2024.